Phase 1Recruiting
Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance. (UPGRADE)
Alpha to Beta Cell Communication in Health and Disease
- Sponsor
- David D'Alessio, M.D. (Academic or other)
- Enrolment
- 30 planned
- Conditions
- Diabetes (DM)
- Interventions
- Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min; Dexamethasone; Dextrose 20% solution; Dextrose 20% solution
- Ages
- adults
- Registry
- NCT07224334
From the registry
Glucagon secretion from α-cells has long been viewed as primarily a counterregulatory mechanism - e.g. an agent with a role to prevent blood sugar from decreasing to levels that compromise function. Our group, along with other researchers, have begun to identify a much more complex role for α-cells, raising questions about when and how glucagon may influence blood glucose levels. This proposal looks to detail proglucagon peptide secretion from α-cells and the impact this has on β-cell function and glucose tolerance, in preclinical studies of human islets and translational studies in human subjects. This protocol registration describes Aim 2 from this NIH grant which involves 2 study populations and separate protocols but addresses a common question. Aim 3 in the grant is focused on a separate hypothesis and will be conducted and published separately from Aim 2.
Primary outcomes
- Insulin secretion with and without exendin-9: Aims 2A and 2B